Immunovant (IMVT) Other financing activities (2019 - 2026)
Immunovant (IMVT) reported Other financing activities of -$82000.0 for Q1 2026, down 125.71% on a YoY basis from $319000.0 in Q1 2025, and down 125.71% quarter-over-quarter from $319000.0 in Q1 2025.
Immunovant (IMVT) Other financing activities (2019 - 2026) Analysis & Trends
Immunovant has reported Other financing activities for 4 years, with the latest figure at -$82000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other financing activities fell 125.71% year-over-year to -$82000.0; the trailing twelve-month figure through Mar 2026 stood at $237000.0 (down 25.71% YoY), and the FY2026 full-year result was $504000.0, up 57.99% from the prior year.
- Other financing activities for Q1 2026 stood at -$82000.0, down from $319000.0 in the prior quarter.
- The five-year high for Other financing activities was $319000.0 in Q1 2025, with the low at -$82000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Immunovant | 5.71 Bn | 5.71 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -82,000.00 |
| Mar 31, 2026 | -82,000.00 |
| Mar 31, 2025 | 319,000.00 |
| Mar 31, 2025 | 319,000.00 |
| Dec 31, 2020 | 261,000.00 |
| Dec 31, 2020 | 261,000.00 |
| Sep 30, 2020 | 373,000.00 |
| Sep 30, 2020 | 373,000.00 |
| Jun 30, 2020 | 602,000.00 |
| Jun 30, 2020 | 602,000.00 |
| Mar 31, 2020 | 190,000.00 |
| Mar 31, 2020 | 190,000.00 |
| Dec 31, 2019 | 2.36 Mn |
| Dec 31, 2019 | 2.36 Mn |
| Sep 30, 2019 | 582,415.00 |
| Sep 30, 2019 | 582,415.00 |
| Jun 30, 2019 | 28,000.00 |
| Jun 30, 2019 | 28,000.00 |
| Mar 31, 2019 | 176,750.00 |
| Mar 31, 2019 | 176,750.00 |